Literature DB >> 32946921

Advances on erythrocyte-mimicking nanovehicles to overcome barriers in biological microenvironments.

Flávia Castro1, Cláudia Martins2, Maria José Silveira2, Rui Pedro Moura3, Catarina Leite Pereira1, Bruno Sarmento4.   

Abstract

Although nanocarriers offer many advantages as drug delivery systems, their poor stability in circulation, premature drug release and nonspecific uptake in non-target organs have prompted biomimetic approaches using natural cell membranes to camouflage nanovehicles. Among them, erythrocytes, representing the most abundant blood circulating cells, have been extensively investigated for biomimetic coating on artificial nanocarriers due to their upgraded biocompatibility, biodegradability, non-immunogenicity and long-term blood circulation. Due to the cell surface mimetic properties combined with customized core material, erythrocyte-mimicking nanovehicles (EM-NVs) have a wide variety of applications, including drug delivery, imaging, phototherapy, immunomodulation, sensing and detection, that foresee a huge potential for therapeutic and diagnostic applications in several diseases. In this review, we summarize the recent advances in the biomedical applications of EM-NVs in cancer, infection, heart-, autoimmune- and CNS-related disorders and discuss the major challenges and opportunities in this research area.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomimetic carriers; Drug delivery; Nanotechnology; Red blood cells

Year:  2020        PMID: 32946921     DOI: 10.1016/j.addr.2020.09.001

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  9 in total

1.  Evolution of drug delivery systems: From 1950 to 2020 and beyond.

Authors:  Haesun Park; Andrew Otte; Kinam Park
Journal:  J Control Release       Date:  2021-12-29       Impact factor: 11.467

2.  Erythrocyte membrane-camouflaged nanoparticles as effective and biocompatible platform: Either autologous or allogeneic erythrocyte-derived.

Authors:  Jun Dai; Zhaojun Chen; Shixuan Wang; Fan Xia; Xiaoding Lou
Journal:  Mater Today Bio       Date:  2022-05-05

Review 3.  Extracellular Vesicles from Red Blood Cells and Their Evolving Roles in Health, Coagulopathy and Therapy.

Authors:  Kiruphagaran Thangaraju; Sabari Nath Neerukonda; Upendra Katneni; Paul W Buehler
Journal:  Int J Mol Sci       Date:  2020-12-25       Impact factor: 5.923

Review 4.  Thrombus-Targeting Polymeric Nanocarriers and Their Biomedical Applications in Thrombolytic Therapy.

Authors:  Qixiao Guan; Hongjing Dou
Journal:  Front Physiol       Date:  2021-11-30       Impact factor: 4.566

5.  Effective Triple-Negative Breast Cancer Targeted Treatment Using iRGD-Modified RBC Membrane-Camouflaged Nanoparticles.

Authors:  Jingbin Huang; Wenjing Lai; Qing Wang; Qin Tang; Changpeng Hu; Min Zhou; Fengling Wang; Dandan Xie; Qian Zhang; Wuyi Liu; Zhe Zhang; Rong Zhang
Journal:  Int J Nanomedicine       Date:  2021-11-10

Review 6.  Cell-derived membrane biomimetic nanocarriers for targeted therapy of pulmonary disease.

Authors:  Xixi Zheng; Tianyuan Zhang; Ting Huang; Yanjun Zhou; Jianqing Gao
Journal:  Int J Pharm       Date:  2022-04-18       Impact factor: 6.510

Review 7.  Research update on cell membrane camouflaged nanoparticles for cancer therapy.

Authors:  Chengfang Wang; Size Wu
Journal:  Front Bioeng Biotechnol       Date:  2022-08-05

Review 8.  Harnessing Protein Corona for Biomimetic Nanomedicine Design.

Authors:  Zhidong Chen; Xu Chen; Juyang Huang; Junqing Wang; Zhe Wang
Journal:  Biomimetics (Basel)       Date:  2022-09-06

9.  From blood to brain: blood cell-based biomimetic drug delivery systems.

Authors:  Yong-Jiang Li; Jun-Yong Wu; Jihua Liu; Xiaohan Qiu; Wenjie Xu; Tiantian Tang; Da-Xiong Xiang
Journal:  Drug Deliv       Date:  2021-06-18       Impact factor: 6.819

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.